Holistic Treatment For ADHD and Dual Diagnosis in Virginia
Many adults discover their ADHD diagnosis only after seeking treatment for addiction. Dual diagnosis treatment recognizes that ADHD and substance use disorder frequently fuel each other, with millions of adults in addiction treatment having co-occurring ADHD.
Successful recovery requires addressing both conditions simultaneously through integrated care that combines ADHD management with addiction treatment. Alpas Wellness provides specialized treatment in Virginia, offering comprehensive programs that treat both ADHD and substance use disorder within a unified, unique treatment plan.
Frequently Asked Questions About Addiction and ADHD
Can ADHD medications be safely used during substance abuse treatment in Virginia?
Yes, treatment centers in Virginia can incorporate medication management for attention deficit hyperactivity disorder during addiction treatment when supervised by experienced healthcare providers. Dual diagnosis treatment programs often use evidence-based approaches that include non-stimulant medications to avoid triggering substance use disorder.
When treating co-occurring disorders, mental health professionals in treatment facilities carefully monitor medication-assisted treatment protocols. The personalized care approach ensures that ADHD interventions support rather than complicate the recovery journey from substance abuse.
Why do people with ADHD develop co-occurring mental health disorders and addiction?
People with ADHD face higher rates of substance abuse disorder because they often self-medicate to manage their mental health challenges. This pattern emerges when people use substances as coping mechanisms for untreated mental health conditions. ADHD frequently co-occurs with anxiety disorder, bipolar disorder, and other mental health issues, creating complex behavioral health needs. Treatment programs addressing these co-occurring disorders must provide comprehensive care that recognizes how ADHD symptoms increase vulnerability to drug addiction and other substance abuse patterns.
What happens if a loved one receives addiction treatment without addressing their ADHD?
When treatment approaches focus only on substance abuse without addressing underlying mental health disorders, lasting recovery becomes unlikely. Effective treatment for dual diagnosis requires integrated interventions that include cognitive behavioral therapy, dialectical behavior therapy, and other evidence-based therapies. Without proper ADHD treatment, individuals struggle with long-term recovery because untreated symptoms undermine their well-being. Treatment centers like Alpas NOVA offer individualized care plans combining detox, inpatient or outpatient programs, group therapy for ADHD, and aftercare services that address the whole person’s specific needs for sustainable wellness.
Elmaghraby, R., & Garayalde, S. (2022, June). What is ADHD? American Psychiatric Association. https://www.psychiatry.org/patients-families/adhd/what-is-adhd on May 13, 2025
National Institute of Mental Health. (2024, December). Attention-Deficit/Hyperactivity disorder. Www.nimh.nih.gov; National Institute of Mental Health. https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd on May 13, 2025
Zulauf, C. A., Sprich, S. E., Safren, S. A., & Wilens, T. E. (2014). The Complicated Relationship Between Attention Deficit/Hyperactivity Disorder and Substance Use Disorders. Current Psychiatry Reports, 16(3). https://pmc.ncbi.nlm.nih.gov/articles/PMC4414493/ on May 13, 2025
Gujska, J. H., Silczuk, A., Madejek, R., & Szulc, A. (2023). Exploring the Link Between Attention-Deficit Hyperactivity Disorder and Cannabis Use Disorders: A Review. Medical Science Monitor, 29. https://pmc.ncbi.nlm.nih.gov/articles/PMC10171029/ on May 13, 2025
Davis, C., Cohen, A., Davids, M., & Rabindranath, A. (2015). Attention-Deficit/Hyperactivity Disorder in Relation to Addictive Behaviors: A Moderated-Mediation Analysis of Personality-Risk Factors and Sex. Frontiers in Psychiatry, 6(47). https://pmc.ncbi.nlm.nih.gov/articles/PMC4403287/ on May 13, 2025